Iron Overload, Chelation Therapy and Survival in Lower-Risk Myelodysplastic Syndromes: State of the Evidence

References (30)

1. 1 International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes [DOI]
2. 2 Proposals for the classification of the myelodysplastic syndromes [DOI]
3. 3 World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997 [DOI]
4. 4 Revised International Prognostic Scoring System for Myelodysplastic Syndromes [DOI]
5. 5 Clinical and biological implications of driver mutations in myelodysplastic syndromes [DOI]
6. 6 Clinical Effect of Point Mutations in Myelodysplastic Syndromes [DOI]
7. 7 Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes [DOI]
8. 8 Survival in Medically Treated Patients with Homozygous β-Thalassemia [DOI]
9. 9 Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making [DOI]
10. 10 Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major [DOI]
11. 11 Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs [DOI]
12. 12 Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes [DOI]
13. 13 A prognostic score for patients with lower risk myelodysplastic syndrome [DOI]
14. 14 Myelodysplastic Syndromes [DOI]
15. 15 Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) [DOI]
16. 16 Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries [DOI]
17. 17 Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM [DOI]
18. 18 Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome [DOI]
19. 19 Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes [DOI]
20. 20 Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry [DOI]
21. 21 Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry [DOI]
22. 22 Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis [DOI]
23. 23 Impact of Iron Chelation Therapy on Overall Survival and AML Transformation in Lower Risk MDS Patients Treated At the Moffitt Cancer Center [DOI]
24. 24 Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up [DOI]
25. 25 Inhibiting the hepcidin inhibitor for treatment of iron overload [DOI]
26. 26 Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices [DOI]
27. 27 Closing the Iron Gate [DOI]
28. 28 48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients [DOI]
29. 29 The IRON2 Study. A Retrospective Observational Study to Describe the Evolution of Iron Overload in Patients with Low-Risk Myelodysplastic Syndrome [DOI]
30. 30 Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes [DOI]

Cited by 0

No indexed citations yet.

Related research

• The Intersection of Hepcidin and Polycystic Ovary Syndrome: A Review of Current Understanding — shares topic coverage
• Correlation of Glucose Tolerance Disorders with Glycated Albumin and HbA1c in Transfusion‑Dependent Children with Beta Thalassemia — shares topic coverage
• Comparison of Plasma Glucose, Serum Ferritin, HbA1c and Serum Nitric Oxide Levels between Diabetic and Non Diabetic Individuals: An Indian Scenario — shares topic coverage
• The Association between Micronutrients Levels and Gestational Diabetes: A Cross Sectional Study in Ashanti Region — shares topic coverage
• Beta Thalassemia Major: Overview of Molecular Etiology, Pathophysiology, Current and Novel Therapeutic Approaches — shares topic coverage